On October 10, 2016 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that it will host a Key Opinion Leader lunch discussion on novel approaches to targeting the RAS Pathway in oncology, including the Company’s late-stage drug candidate, rigosertib, a small molecule that inhibits cellular signaling by interacting with the RAS-binding domain (RBD) of RAS effector proteins (Press release, Onconova, OCT 10, 2016, View Source [SID:SID1234515713]). The event and live webcast will take place on Monday, October 17, from 12:00 PM-1:30 PM Eastern Time in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The meeting will feature presentations by two pioneers in the area of RAS biology. Dr. Channing J. Der, a member of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center and the Kenan Distinguished Professor in the Department of Pharmacology at UNC-Chapel Hill, and Dr. E. Premkumar Reddy, Professor in the Department of Oncological Sciences and the Department of Structural & Chemical Biology and Director of the Experimental Cancer Therapeutics Program at the Tisch Cancer Institute at Mount Sinai School of Medicine. Following these presentations, Onconova’s management team will provide an overview of the Company’s ongoing clinical development work with lead product candidate, rigosertib, a small molecule intended to treat patients with myelodysplastic syndromes (MDS). Onconova is actively enrolling patients in its global Phase 3 INSPIRE trial with IV rigosertib, and has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) related to a combination therapy with oral rigosertib and azacitidine. A Q&A session with the featured experts and management will follow the presentations.
This event is intended for institutional investors and sell-side analysts. To reserve a place, please contact Mac McDonald at 212-915-2567 or via e-mail at [email protected]. A live webcast and subsequent replay of the event will be available at View Source